The applications submitted to the ‘Infectious Diseases Catalyst Grants 2026’ will be assessed by the Committee for Infectious Diseases (CID), which was established in 2026 and approved by the Novo Nordisk Foundation Board of Directors to make the granting decisions for this call. The committee will consist of up to seven members with relevant and complementary scientific and translational expertise, with a diverse representation from various, but primarily European, institutions. The committee members are experts within various fields of infectious diseases research, including pandemic influenza and AMR.
The committee composition will be made publicly available in Spring 2026 on this webpage.
